Since monocytes and macrophages that arise during the culture of bone marrow progenitor cells are potential sources of interleukin 6 (Ib6), we investigated whether auto-or paracrine production of this factor is involved in colony formation by normal hematopoietic progenitor cells. We added a polyclonal anti-Ib6 antiserum and a monoclonal anti-Ib6 antibody to cultures of monocyteand T cell-depleted bone marrow cells. Colony formation was stimulated with granulocyte/ monocyte-colony-stimulating factor (GM-CSF), monocyte-CSF, or II.-3. Addition of anti-IL-6 antibody resulted in decreased numbers of monocytic colonies to 40-50% of control values, whereas the numbers of granulocytic colonies were not altered. The inhibitory effect was preserved in cultures of CD34 +-enriched bone marrow cells. As a second approach, we added a monoclonal antibody directed against the Ib6 receptor to cultures of monocyte-and T cell-depleted bone marrow cells. This antibody almost completely inhibited the growth of monocytic colonies, again without decreasing the number of granulocytic colonies. Finally, the importance of IL-6 in monocytopoiesis was demonstrated in serum-deprived bone marrow cultures: addition of exogenous IL-6 to cultures stimulated with GM-CSF resulted in increased numbers of monocytic colonies. Our results indicate that the permissive presence of IL-6 is required for optimal monocytic colony formation by bone marrow progenitor cells.
I
b6 is involved in the development of B and T lympho-, cytes and is one of the major cytokines that induce the acute phase response upon infection or injury (1) . In addition, IL-6 has been attributed a role in myelopoiesis. Alone, IL-6 does not induce colony formation by bone marrow progenitor cells, but it enhances Ib3-stimulated proliferation of myeloid progenitor cells (2) and the formation of monocytic colonies at suboptimal concentrations of monocyte (M)-CSF (3). Furthermore, it stimulates thrombocytopoiesis, both in vitro and in vivo (4, 5) .
Colony formation assays have proved to be invaluable in the study of factors that regulate hematopoiesis. To study possible direct effects of cytokines, suspensions of purified bone marrow progenitor cells may be used. However, autocrine or paracrine production of cytokines by progenitor cells or their offspring may still influence colony formation. Since monocytic cells are potent producers of Ib6 (1, 6) , and these cells originate in cultures of bone marrow progenitor cells, we investigated the role of auto-and paracrine production of IL-6 on the development of colonies using neutralizing antibodies against Ib6 and the Ib6R. Since monocytes rapidly lose viability in serum-free conditions (7), we also tested whether addition of Ib6 resulted in enhanced monocytic colony formation in serum-deprived cultures.
Materials and Methods
Cytokines and Antibodies. Human rlb6 was kindly provided by Dr. L. A. A,arden (CLB, Amsterdam, The Netherlands); human rGM-CSF was provided by Sandoz Pharma BV (Uden, The Netherlands); human rM-CSF was a gift from Dr. P. Ralph (Cetus Corp., Emeryville, CA; human rG-CSF was a gift from Dr. B. Altrock (Amgen, Thousand Oaks, CA); human rib3 was a gift from Dr. G. Wagemaker (Netherlands Organization for Applied Scientific Research, Delft, The Netherlands). Mouse anti-human Ib6 mAb (neutralizing 10 U/ml II.-6 at a dilution of 1:10-s) and a polyclonal rabbit anti-human IL-6 (neutralizing 10 U/ml II.,6 at a dilution of 3:10 -4) were raised against purified rib6. Anti-IL-6R antibody, PM-1 (8), was kindly provided by Dr. T. Kishimoto (Osaka University, Japan). This antibody competes with Ib6 for binding to the Ib6R (10 #g/ml neutralizes the activity of 2 ng/ml IL-6).
Cell Pre~rations. In serum-deprived cultures, the FCS was replaced by 2 x 10 -4 M cholesterol (Sigma Chemical Co.) and 10 #g/ml insulin (Sigma Chemical Co.) as described (11) . Colony formation was induced with G-CSF (10 ng/ml), M-CSF (1,000 U/ml), Ib3 (50 ng/ml), or GM-CSF (50 U/ml). Six replicates of 100/zl were plated in flat-bottomed microtiter plates (Greiner, Alphen a/d Rijn, The Netherlands), except for experiments with CD34 ÷ cells, where two replicates of I ml were plated in 25-mm petri dishes (Greiner). Cultures were kept at 37°C in a fully humidified, 5% COs atmosphere. CFU-G (>50 granulocytes) and CFU-M (>20 macrophages) were scored on day 14. Colonies were mass harvested or picked individually with a micropipette, and stained with ANAl/ or May-Griinwald Giemsa.
Results

Effect of Anti-IL6 Antibody on Monocytic Colony Formation.
We investigated the role of endogenously produced I1.6 in serum-containing cultures of monocyte-and T cell-depleted bone marrow cells. Increasing concentrations of an anti-I1,6 mAb were added to cultures that were stimulated with GM-CSF (Fig. 1) . A dose-dependent reduction of the number of monocytic colonies to 40% of control values was observed, with the number of granttlocytic colonies unaffected. A similar effect was observed when a polyclonal anti-I1,6 antiserum was used. In the presence of this antiserum, CFU-G growth was 110 ± 27% and CFU-M growth was 50 ± 11% of control growth (mean ± SD, n = 5).
To test whether the specific inhibition of monocytic colony formation was dependent on the growth factor used to induce colony formation, we added anti-I1.6 mAb to cultures that were stimulated with G-CSF, M-CSF, or IL-3 (Fig. 2) . In these studies, a similar inhibition of monocytic colony formation was observed, with the number of granulocytic colonies again unaffected. Inhibition of monocytic colony formation was not due to nonspecific toxicity of the antibody, since the numbers of granulocytic colonies were not affected, and the effect could be reversed by the addition of excess concentrations of exogenous I1,6 (200 ng/ml) (Fig. 2) . Dose-dependent suppression of monocytic colony formation was preserved to the same degree in cultures of CD34 + bone marrow cells stimulated with GM-CSF (50 U/ml). Anti-Ib6 mAb at a dilution of 1:10 s to 1:200 suppressed CFU-M growth to 56 ± 5% (n = 5, duplicate cultures) of control values, whereas the number of granulocytic colonies was not affected. Mean control growth was 17 CFU-G and 36 CFU-M/IO 3 cells.
Effect of Anti-IL.6R Antibody on Monocytic Colony Formation.
To further substantiate the role of II.6 in monocytic colony formation, we tested whether blocking of the I1.6R by an anti-IL-6R antibody was able to inhibit monocytic colony formation. Almost complete inhibition (to 2% of control values, n = 4) of monocytic colony formation was observed in cultures containing the anti-I1.6R antibody. The number 
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Effect of anti-IL-6R antibody (10/~g/ml) on granulocytic and Figure 3 . monocytic colony formation by monocyte-and T cell-depleted bone marrow cells stimulated with GM-CSF (50 U/ml). Mean values of four experiments _+ SD are given.
of granulocytic colonies was unaffected (Figs. 3 and 4) , indicating that the effect was not due to toxicity of the antibody. Additionally, specificity could be confirmed since this antibody competes with IL-6 for binding to the Ib6R (8) . In two cases tested, inhibition of monocytic colony formation to 2% and 3% of control values was reversed to 112% and 
Effect of lI.,6 on Monocytic Colony Formation in Serum-deprived Cultures.
Since monocytes rapidly lose viability in sernmfree conditions, and serum may contain IL-6 or IL-6-inducing factors, we tested whether IL-6 was able to enhance monocytic colony formation in serum-deprived cultures of monocyte-and T cell-depleted bone marrow cells. In the presence of GM-CSF (50-500 U/ml), low numbers of monocytic colonies were obtained. In two experiments, addition of IL-6 resulted in a four-and eightfold increase in the number of monocytic colonies (Table 1 ). The number of granulocytic colonies was not affected. 
Discussion
In this report we show by three different approaches that IL-6 plays an important role in monocyfic colony formation by bone marrow progenitor cells. Inhibition of monocytic colony formation by anti-IL-6R antibody was much more pronounced (98% inhibition) than inhibition by anti-Ib6 antibodies (50-60% inhibition). This difference might be explained by the existence of high and low affinity types of receptor-ligand binding between IL-6 and its receptor (12) , the anti-IL-6 antibodies being able to compete only with the low affinity binding. Alternatively, the IL-6R may bind to more than one ligand, being the anti-Ib6R antibody able to block binding of both ligands.
These data underscore that in standard bone marrow cultures, on which the concept of regulation of hematopoiesis largely has been based, intermediate production of cytokines by the progenitor cells or their offspring may play an important role.
Several hypotheses may explain our data. IL-6 may act as a competence factor, inducing sensitivity of progenitor cells to growth factors, or as a progression factor, enabling cells to proceed through the restriction point of the cell cycle. Alternatively, I1:6 may enhance progenitor cell survival by preventing apoptosis (programmed cell death). Recently, several authors suggested that hematopoietic growth factors prevent apoptosis in hematopoietic progenitor cells (13) (14) (15) . Cells from I1:3, GMoCSF-, and G-CSF-dependent murine cell lines, died by apoptosis upon withdrawal of the relevant growth factor. Remarkably, I1:6 inhibited apoptosis that was induced by the expression of the putative tumor-suppressor protein p53 in a murine myeloid leukemia cell line (19). Serum starvation of human peripheral blood monocytes causes apoptoffs, which can be prevented by the addition of I1:1~8, TNF-c~, or LPS (7). Although Ib6 did not prevent apoptosis in these experiments, prevention of apoptosis by Ib6 in more immature monocytic precursors cells, as studied in our experiments, remains possible.
If Ib6 has a similar permissive role in monocytopoiesis in vivo, this would add another level of control over the production of monocytes and macrophages. The high concentration of I1:6 in inflammatory tissues and the high titer in plasma upon infection and injury may be of relevance in this respect.
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